key: cord-0272403-h4pe3to1
authors: Weinstein, Jules B.; Bates, Timothy A.; Leier, Hans C.; McBride, Savannah K.; Barklis, Eric; Tafesse, Fikadu G.
title: A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants
date: 2022-01-20
journal: bioRxiv
DOI: 10.1101/2022.01.18.476801
sha: 78f6a6f207dc9b6f6967269d62688437b49c2f75
doc_id: 272403
cord_uid: h4pe3to1

The spike glycoprotein of SARS-CoV-2 engages with human angiotensin-converting enzyme 2 (ACE2) to facilitate infection. Here, we describe an alpaca-derived heavy chain antibody fragment (VHH), saRBD-1, that disrupts this interaction by competitively binding to the spike protein receptor-binding domain. We further generated an engineered bivalent nanobody construct engineered by a flexible linker, and a dimeric Fc conjugated nanobody construct. Both multivalent nanobodies blocked infection at picomolar concentrations and demonstrated no loss of potency against emerging variants of concern including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Epsilon (B.1.427/429), and Delta (B.1.617.2). saRBD-1 tolerates elevated temperature, freeze-drying, and nebulization, making it an excellent candidate for further development into a therapeutic approach for COVID-19.

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-24

CoV-2), is an ongoing global health crisis with over 230 million cases, 4.8 million deaths world-25 wide as of October 2021 (Dong et al., 2020) . While several effective vaccines have been 26 developed, concern about potential future surges of infections remain, due to the proliferation 27 and spread of multiple variant strains, combined with waning protection from vaccination (Levin 28 et al., 2021; Shrotri et al., 2021) . It is anticipated that additional variants will continue to emerge, 29 and the slow pace of global vaccination creates greater opportunity for emergence and spread 30 of vaccine resistant variants (Luo et al., 2021) . 31 32 SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus, and a member of the 33 Coronaviridae family, so named for the crown-like protrusions visible on their outer membranes 34 in EM micrographs (Huang et al., 2020) . Four structural proteins are encoded by SARS-CoV-2: 35 spike (S), envelope, membrane, and nucleocapsid . Homotrimers of the S 36 glycoprotein form the characteristic crown-like protrusions on the virion surface, where it 37 facilitates entry into cells through its interaction with the cell surface protein angiotensin-38 converting enzyme 2 (ACE2) (Hoffmann et al., 2020) . Each monomer of S is composed of two 39

from an alpaca immunized with RBD. A) Schematic illustration of the immunization and VHH 121 library construction pipeline. Alpacas were immunized over an 8-week period after which PBMC 122 mRNA was isolated and processed into a VHH gene library. This library was transformed into 123 phage-competent bacteria to generate a bacteriophage library, which was panned against 124 SARS-CoV-2 S to enrich for binding clones. Clones were characterized through ELISAs on RBD 125 and preliminary neutralization of S-pseudotyped lentivirus. B) Representative 126 immunofluorescence staining showing saRBD-1 VHH specifically associates with SARS-CoV-2 127 infected VeroE6 cells. Cells were infected with SARS-CoV-2 virus for 24 hours. Fixed cells were 128 stained with either saRBD-1 or control VHH (VHH52) followed by anti-VHH secondary (green). 129

CoV-2 S-transfected cells are specifically bound by saRBD-1 at levels detectable by flow 131 cytometry. 293T cells transfected with full-length SARS-CoV-2 S were stained with either VHH 132 saRBD-1 (green) or VHH52 (red) control. 133 134 VHH saRBD-1 binds SARS-CoV-2 spike and receptor domain with high affinity 135 D re -We determined the subunit specificity of saRBD-1 by ELISA on purified full-length trimeric S, S1 136 (residues 14-684), RBD (residues 319-541), and S2 (residues 685-1273) proteins ( Figure 2A) . 137 We found that saRBD-1 bound to full-length trimer with a 50% maximal binding response (EC 50 ) 138 of 100 pM, to S1 with an EC 50 of 200 pM, and to RBD with an EC50 of 607 pM, while S2 139 showed no detectable binding, demonstrating that saRBD-1 binds specifically to the RBD 140 subunit of the S protein ( Figure 2B, D) . Due to the promising initial binding characteristics of 141 saRBD-1, we next investigated the binding kinetics in greater detail using bio-layer 142 interferometry (BLI), which measures the effective mass change at the surface of a sensor tip. 143

As expected, the S2 protein control yielded no binding ( Figure 1C , D). However, BLI tips loaded 144 with RBD measured a dissociation constant (K D ) of 750 pM for saRBD1, while tips coated with 145 S1 yielded a K D 1880 pM. S trimer loaded tips showed the strongest binding with a K D of 674 146 pM, consistent with our ELISA results. These K D 's are lower than the previously reported 15 nM 147 K D of the RBD-ACE2 interaction, suggesting that saRBD-1 binds SARS-CoV-2 with at least an 148 order of magnitude greater affinity than ACE2 (Glasgow et al., 2020) . 149 150 To more thoroughly examine this, we performed BLI-based competition assays to determine if 151 saRBD-1 is able to block the RBD-ACE2 interaction ( Figure 2E ). In this assay, BLI tips were first 152 loaded with RBD followed by varying concentrations of saRBD-1 VHH to block the RBD binding 153 sites before finally transferring to a solution with a fixed concentration of ACE2. We found that 154 saRBD-1 bound competitively with ACE2, and that a concentration of 6 nM of saRBD-1 was 155 sufficient to block 50% of ACE2 binding. These results indicated that saRBD-1 binds specifically 156 to the RBD subunit of native trimeric S protein with picomolar affinity and blocks the subsequent 157 interaction of RBD with ACE2. on plates coated with SARS-CoV-2 RBD, S1, S2, and full-length S trimer where saRBD-1 is 163 seen to bind RBD, S1, and full-length S trimer, but not S2. Curves show the average of 3 164 replicate experiments. C) Representative BLI curves of saRBD-1 binding kinetics experiments 165 on SARS-CoV-2 S RBD, S1, S2, and full-length trimer where saRBD-1 is seen to bind RBD, S1, 166 and full-length S trimer, but not S2. Biotinylated spike constructs were pre-bound to streptavidin 167 biosensor tips, after which association and dissociation steps were carried out in saRBD- 

As an initial test of neutralization, we performed immunofluorescence microscopy on Vero E6 179 cells infected in the presence of 179 nM of either saRBD-1, which we found to completely block 180 infection, or 179 nM control VHH52 ( Figure 3A) . Infection was visualized with the anti-dsRNA 181 antibody. To quantify the neutralizing potency of saRBD-1 we performed experiments for both 182 pseudotyped virus and live SARS-CoV-2. For pseudotyped virus neutralization assays, GFP-183 bearing SARS-CoV-2 S pseudotyped lentivirus was incubated with dilutions of saRBD-1 or 184 control VHH52 before being added to target 293T-ACE2 cells. Successful lentivirus transduction 185 was detected by high-content fluorescence microscopy of GFP signals. The 50% inhibitory 186 concentration (IC 50 ) of the VHH for this lentivirus challenge was 4.26 nM ( Figure 3B ) while 187 VHH52 showed no inhibition. To control for non-specific inhibition of lentivirus transduction, 188 lentivirus was generated pseudotyped with the VSV G protein in lieu of SARS-CoV-2 S; VSV G 189 pseudotyped virus was not neutralized by saRBD-1 ( Figure 3B ). 190

To determine VHH inhibitory activities against live SARS-CoV-2 virus, focus forming assays 192 were performed using SARS-CoV-2 WA1/2020 strain and saRBD-1. For the assay, Vero E6 or 193 human colorectal epithelial (Caco-2) cells were infected with SARS-CoV-2, then stained with 194 anti-S alpaca polyclonal sera as a primary antibody and an HRP-conjugated secondary 195 antibody, facilitating visualization of SARS-CoV-2 infected cells ( Figure 3C , D). The 50% focus 196 reduction neutralization titer (FRNT 50 ) was found to be 5.82 nM for Vero E6, and 7.4 nM for 197

Caco2 ( Figure 3E ). In comparison, the non-neutralizing VHH52 failed to decrease foci. Thus, it is evident that monovalent saRBD-1 is a potent neutralizer of live SAR-COV-2 in vitro, even at 199 low nanomolar concentrations. (Fc-saRBD-1) to RBD, we utilized ELISA and BLI ( Figure 4B -C, Figure S2 ). The EC 50 of Fc-229 saRBD-1 as measured by ELISA was 392 pM, a 50% stronger affinity as compared to 230 monovalent saRBD-1. The K D of Fc-saRBD-1 as measured by BLI was 302 pM, primarily driven 231 by a 3-fold reduction in the K OFF compared to monovalent saRBD-1. Using our pseudovirus 232 neutralization assay, the neutralization ability of the Fc-saRBD-1 dimer improved to an IC 50 of 233 100 pM, over a 40-fold improvement compared to monomeric saRBD-1 ( Figure 4D 

nebulization 258

One of the major advantages of VHHs over conventional antibodies is their inherent stability. 259

We evaluated the stability of saRBD-1 by subjecting it to some of the conditions that are likely to 260 be encountered during production, transport, and delivery of protein-based therapeutics we 261 evaluated the stability of saRBD-1 in elevated temperature, lyophilization, and nebulization. We 262 treated VHH to each condition, then measured of protein loss, binding kinetics, and neutralizing 263 ability of the treated VHH aliquots. Aliquots of saRBD-1 were incubated for 1 hour at 50°C then 264 centrifuged to remove aggregates before measurement of protein loss by OD 280 , which showed 265 a 19% reduction. The treated aliquots were then checked by BLI on RBD ( Figure 5G , I), which 266 showed minimal loss of activity concomitant with the reduction in measured protein 267 concentration. Similar measurements were performed using lyophilized (29% protein loss) and 268 nebulized (77% protein loss) samples. Nebulization is known to be a harsh process, particularly 269 when performed in unmodified PBS solution with a jet nebulizer, and our numbers mirror 270 previous reports of 4-fold loss of activity after nebulization with an ultrasonic nebulizer (Schoof 271 et al., 2020). In total, we found that the K D was 938 pM for heat treatment, 936 pM for 272 lyophilized, and 3.65 nM for aerosolized, amounting to 1.25-fold, 1.25-fold, and 4.8-fold 273 increases respectively, which align with our protein loss determinations. 274

To assay effects of these treatments on neutralizing activity, we carried out focus forming 276 assays in VeroE6 cells utilizing the heat treated, lyophilized, and nebulized saRBD-1 samples 277 ( Figure 3H , J). We found that 50°C treated, lyophilized, and nebulized saRBD-1 yielded 278 FRNT 50 s of 3.00 nM, 3.74 nM, and 9.01 nM respectively. In comparison, untreated saRBD-1 279 yielded a FRNT 50 of 5.82 nM. Therefore, only nebulization reduced saRBD-1 neutralizing 280 capability, with a 1.56-fold reduction. Overall saRBD-1 appears functionally stable, and it 281 maintains nanomolar neutralization activity towards RBD even after destabilizing treatments. 282 

Because of the prevalence of SARS-CoV-2 variant strains of concern (VOCs) significantly 297 divergent from the base strain ( Figure 6A ), we sought to test saRBD-1's affinity for mutated 298 RBD-N501Y and neutralizing abilities against clinical VOC isolates We generated a variant RBD 299 to test saRBD-1-RBD interactions. Using site directed mutagenesis, we created a spike and 300 o 1 D RBD variant that contained the N501Y mutation found in several of the circulating VOCs ( Figure  301 6B). Using BLI, we found binding of saRBD-1 to RBD-N501Y was similar to WT saRBD-1 302 ( Figure 6C , D), with a K D of 767 pM compared to the WT value of 750 pM ( Figure 6E ). The 303 affinity of saRBD-1 against both wild-type and mutant RBD constructs were stronger than the 15 304 nM affinity of RBD for ACE2 (Glasgow et al., 2020) , indicating that the N501Y amino acid 305 change is unlikely to affect neutralization. interferometry (BLI) competitive binding assay. In this assay, SARS-CoV-2 spike RBD protein 349 was attached to a sensor and first exposed to saRBD-1, which bound strongly during the first 350 300 seconds. In the subsequent step, the sensors were transferred to solutions containing the 351 representative monoclonal antibodies. SaRBD-1 successfully blocked B38 from binding, 352 indicating that they likely bind to overlapping epitopes ( Figure 7B ). The class 2 & 3 antibodies 353 were not affected by saRBD-1. A control experiment confirmed that B38 binds successfully 354 when saRBD-1 was absent ( Figure 7C ). These results were recapitulated with a dimeric Fc-355 saRBD-1 construct (Figure7D) . Hence, saRBD-1 is most likely a class 1 binder. An unlikely alternative is that saRBD-1 binds a distal site non-competitive with the class 3 antibody, but 357 forces RBD into a down conformation unsuitable for B38 binding. 358 359 360 Alpacas were immunized at Capralogics Incorporate (Hardwick, MA). Animals received three 490 immunizations of 1 mg purified SARS-CoV-2 RBD spaced three weeks apart. Blood was 491 harvested 5 days after third immunization. Upon receipt PBMCs were isolated (Eppendorf) and 492 used in an RNA extraction with Qiagen RNeasy mini kit (Qiagen). PBMC RNA, containing VHH 493 genes, was converted into cDNA using Superscript III reverse transcriptase (Invitrogen). VHH 494 genes were amplified with custom primers specific to short-hinge and long hinge VHH genes 495 appended with Not1 and Asc1 restriction sites (Maass et al., 2007; Schmidt, 2018) . The 496 amplified gene mixture was cloned into a phage-mid plasmid derived from pCANTA5BE, then 497 transformed via electroporation into bacteriophage competent TG1 Escherichia coli for 498 production of a VHH displaying bacteriophage library. The pooled library was rescued at 37 C 499 with shaking and plated. Plates containing serial dilutions were used to estimate total bacterial 500 population, and therefore library diversity. A representative sample of 96 VHH clones were sent 501 for sanger sequencing (Genewiz) to confirm VHH diversity. 293T cells were seeded at 70% confluency on 24 well plates. Cells were then transfected with 1 593 μ g of HDM_IDTSpike_fixK S plasmid as described above. 24 hours after transfection, cells were 594 for 300 seconds in kinetics buffer, association for 300 seconds with antibody diluted in kinetics 652 buffer, dissociation for 750 seconds in plain kinetics buffer, and regeneration by 3 cycles of 20 653 seconds in 10 mM glycine pH 1.7, then 20 seconds in kinetics buffer. All antibodies were run 654 against an isotype control antibody at the same concentration. For competition experiments, 655 biosensors were loaded with RBD similarly to binding experiments, then bound with 50 nM 656 saRBD-1 or 100 nM Fc-saRBD-1 for 300 seconds before transferring to monoclonal antibody 657 diluted in kinetics buffer for 300 seconds (cov2rbdc2-mab10 was used at 20 nM, while srbdc4-658 mab10 and srbdc5-mab10 were used at 10 nM). Data analysis was performed using the 659 ForteBio data analysis HT 10.0 software. Curves were reference subtracted using the isotype 660 control and each cycle was aligned according to its baseline step. K D 's were calculated using a 661 1:1 binding model, and the kinetic parameters (K D , k ON , k OFF ) were averaged from 662 concentrations and replicates, excluding dilutions with an R 2 less than 0.9 or an Rmax more 663 than double the average of other concentrations. 664 665

The neutralization protocol was based on previously reported neutralization methods utilizing 667 SARS-CoV-2 S pseudotyped lentivirus (Crawford et al., 2020) . 293T-ACE2 cells were seeded 668 poly-lysine treated 96-well plates at a density of 10,000 cells per well. Cells were allowed to 669 grow overnight at 37°C. LzGreen SARS-COV-2 S pseudotyped lentiviruses were mixed with 670 saRBD-1, or VHH52 control antibody. Immunized alpaca serum was used as positive 671 neutralization control, while virus alone was used as negative control. Dilutions of antibodies 672 ranged from 177 nM to 170 pm for saRBD-1 and 26.3nM and 25 pM for Fc-saRBD-1, and 6.57 673 nM to 4 pM Bi-saRBD-1. Virus-antibody mixture was incubated at 37C for 1 hour after which 674 polybrene was added up to 5 μ g/ml and the mixture was added to 293T-ACE2 cells. Cells were 675 incubated with neutralized virus for 44 hours before imaging. Cells were fixed with 4% PFA for 1 676 hour at RT. Fixed cells were washed with PBS 2x, then incubated with 10 μ g/ml DAPI for 10 677 minutes at RT, imaged with BZ-X700 all-in-one fluorescent microscope (Keyence). Estimated 678 area of DAPI and GFP fluorescent pixels were calculated with built in BZ-X software (Keyence). 679 680 Focus forming assay (FFA) 681

The FFAs was performed as previously described (Case et al., 2020) . In brief, Vero E6 cells 682 were plated at 20,000 cells/well or Caco-2 cells were plated at 24,000 cells/well in 96-well plates 683 and incubated overnight. Titrated SARS-CoV-2 stocks were diluted to 3,333 ffu/mL. To 20 For ELISA and neutralization data, EC 50 and IC 50 values were calculated using python software 699 pipeline based on input data. Curves were fit to each data set using the same pipeline. 700

For ELISA data, EC 50 were calculated from OD 450 nm signal relative to maximal signal for a 701 given pattern. Background was subtracted, then each was normalized to the maximum value for 702 that antigen. The S2 domain data was analyzed differently, as it was comparable to 

A serological 750 assay to detect SARS-CoV-2 seroconversion in humans

Efficacy and Safety of the mRNA

CoV-2 Vaccine

SARS-CoV-2 756 neutralizing antibody structures inform therapeutic strategies

Neutralization of SARS-CoV-2 variants 759 by convalescent and BNT162b2 vaccinated serum

Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine 762 Immune Serum Samples

Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2

Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 768 Breakthrough Infection

Design, Expression

Characterization of a YFP-Tagged 2019-nCoV Spike Receptor-Binding Domain 771

Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in 774 pathogenesis and protective immunity

Neutralizing Antibody and Soluble ACE2 Inhibition of a 777

Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

Rapid and Direct VHH and Target Identification by Staphylococcal Surface 780 Display Libraries

Resistance of SARS-CoV-2 variants to neutralization by 783 monoclonal and serum-derived polyclonal antibodies

Protocol and reagents for pseudotyping 786 lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays (Microbiology)

Addressing the Cold Reality of mRNA Vaccine Stability

Early Evidence of the Effect of 791 SARS-CoV-2 Vaccine at One Medical Center

Transmission, infectivity, 795 and neutralization of a spike L452R SARS-CoV-2 variant

An interactive web-based dashboard to track COVID-797 19 in real time

Faster Isolation of PBMC Using Ficoll-Paque® Plus in the Eppendorf 799 Multipurpose Benchtop Centrifuges 5920 R and 5910 Ri

801 Implications of antibody-dependent enhancement of infection for SARS-CoV-2 802 countermeasures

Protein and Antibody Engineering by Phage Display

Engineered ACE2 receptor traps potently neutralize SARS-807 CoV-2

Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing (Systems 811 Biology)

Complete Mapping of Mutations to the 814 SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Fusion of the 817 mouse IgG1 Fc domain to the VHH fragment (ARP1) enhances protection in a mouse model of 818 rotavirus

Neutralization of SARS-CoV-2 821 by highly potent, hyperthermostable, and mutation-tolerant nanobodies

An alpaca 824 nanobody neutralizes SARS-CoV-2 by blocking receptor interaction

A bispecific monomeric nanobody induces spike 828 trimer dimers and neutralizes SARS-CoV-2 in vivo

SARS-CoV-2 Cell Entry 831 Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 variants B.1.351 and P.1 835 escape from neutralizing antibodies

Tracking Coronavirus Vaccinations Around the World. The New York Times

Effectiveness of 838 Convalescent Plasma Therapy for COVID-19 Patients in Hunan

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The 842 Lancet

Exploiting Nanobodies' Singular Traits

Neutralizing Antibodies against SARS-CoV-2 and Other 846 Human Coronaviruses

The neutralizing 849 antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

Logistical challenges for

CoV-2 vaccine and a call to research institutions, developers and manufacturers

Viridot: An automated virus 856 plaque (immunofocus) counter for the measurement of serological neutralizing responses with 857 application to dengue virus

Neutralizing antibody levels are highly 860 predictive of immune protection from symptomatic SARS-CoV-2 infection

A therapeutic neutralizing antibody targeting receptor binding domain of 863 SARS-CoV-2 spike protein

Structure-guided multivalent 866 nanobodies block SARS-CoV-2 infection and suppress mutational escape

Tracking Changes in SARS-CoV-2 Spike: 869 Evidence that D614G Increases Infectivity of the COVID-19 Virus

Current status of therapeutic monoclonal 871 antibodies against SARS-CoV-2

Universal protection against 874 influenza infection by a multidomain antibody to influenza hemagglutinin

Waning Immune Humoral Response to BNT162b2 Covid-878 19 Vaccine over 6 Months

The basis of a more contagious 501Y.V1 variant of SARS-CoV-2

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 884 variants

Striking Antibody Evasion Manifested by the Omicron Variant

CoV-2. Nature 1-8

SARS-CoV-2 biology and 889 variants: anticipation of viral evolution and what needs to be done

Alpaca (Lama pacos) 892 as a convenient source of recombinant camelid heavy chain antibodies (VHHs)

Highly synergistic combinations of nanobodies 896 that target SARS-CoV-2 and are resistant to escape

A global database of COVID-19 vaccinations

Cross-neutralization of SARS-CoV-2 by a human 901 monoclonal SARS-CoV antibody

Sensitivity of infectious SARS-CoV

B.1.1.7 and B.1.351 variants to neutralizing antibodies

Nanobody cocktails potently neutralize SARS-CoV-2 907 D614G N501Y variant and protect mice

Fusion of hIgG1-Fc to 910 111In-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time 911 in APP/PS1 mice but does not increase brain uptake

Single Domain Antibodies Derived from Dromedary Lymph Node and Peripheral Blood 915

Lymphocytes Sensing Conformational Variants of Prostate-specific Antigen

Nanobody: outstanding features for 918 diagnostic and therapeutic applications

Phenotypic Lentivirus Screens to Identify Antiviral Single Domain 920

Influenza Virus: Methods and Protocols

An ultrapotent synthetic 924 nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike

Characterization of 926 scFv-Ig Constructs Generated from the Anti-CD20 mAb 1F5 Using Linker Peptides of Varying 927 Lengths

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

Spike-antibody waning after second dose of 933 BNT162b2 or ChAdOx1

Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR 936 and expression vector cloning

Biparatopic nanobodies protect mice from lethal 939 challenge with SARS-CoV-2 variants of concern

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients 942 with Covid-19

Structural Basis for Potent 945 Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies

Structural Basis for Potent 949 Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to 953 its receptor ACE2

Versatile and multivalent nanobodies efficiently neutralize SARS-956 CoV-2

Nanobodies from camelid mice and llamas neutralize 959 SARS-CoV-2 variants

961 (2020). A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and 962 SARS-CoV

The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a 965 multi-center case series

SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral 968 entrance

Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS-CoV-2 Variants

(BioLegend). After live-dead staining, cells were washed 2x with PBS, then fixed with 4% PFA 596 for 15 minutes at RT. Cells were then washed 2x with PBS, then stained with saRBD-1 VHH at 597 2 μ g/ml, VHH52 at 2 μ g/ml or phalloidin-Alexa Fluor 488 (AF488) (ThermoFisher Scientific 598 A12379) for 1 hour at RT. Cells were washed 2x with PBS then treated with anti-VHH biotin 599 (Jackson 128-065-232) secondary antibody (Invitrogen #A16061) was added at 1:500 dilution 600 for 1 hour at RT. Cells were then washed 2x with PBS and treated with streptavidin-AF488 601 (Jackson 016-540-084) for 1 hour at RT. Cells were then resuspended in flow buffer (PBS, 3% 602 FBS, 2mM EDTA), and filtered. Cells were then run on a BD FACSymphony flow cytometer with 603 the assistance of the OHSU flow cytometry core.